Epstein Secrets

ing father of virtual reality, said that Mr. Epstein's ideas did not amount to science, in that they did not lend themselves to rigorous proof. Mr. Lanier said Mr. Epstein had once hypothesized that atoms behaved like investors in a marketplace. Mr. Lanier said he had declined any funding from Mr. Epst

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

ing father of virtual reality, said that Mr. Epstein's ideas did not amount to science, in that they did not lend themselves to rigorous proof. Mr. Lanier said Mr. Epstein had once hypothesized that atoms behaved like investors in a marketplace. Mr. Lanier said he had declined any funding from Mr. Epst

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been

ing father of virtual reality, said that Mr. Epstein's ideas did not amount to science, in that they did not lend themselves to rigorous proof. Mr. Lanier said Mr. Epstein had once hypothesized that atoms behaved like investors in a marketplace. Mr. Lanier said he had declined any funding from Mr. Epst

regulators. But in 2017, the company practically beamed that it had "received clearance from the U.S. Food and Drug Administration for the Company's Investigational New Drug (IND) application lodged last month." The fact that Collins' role in the legislation could also have benefited other companies — and may even have been